C5, HUMAN
Modify Date: 2024-01-02 19:05:51
C5, HUMAN structure
|
Common Name | C5, HUMAN | ||
|---|---|---|---|---|
| CAS Number | 80295-53-0 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | USA | Flash Point | N/A | |
| Name | C5, HUMAN |
|---|
| Storage condition | −70°C |
|---|
| Hazard Codes | B |
|---|---|
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
|
Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
N. Engl. J. Med. 350 , 552-559, (2004) Paroxysmal nocturnal hemoglobinuria (PNH) arises from a somatic mutation of the PIG-A gene in a hematopoietic stem cell and the subsequent production of blood cells with a deficiency of surface protei... |
|
|
Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
Mini Rev. Med. Chem. 11 , 528-535, (2011) Paroxysmal nocturnal hemoglobinuria (PNH) is a hematological disorder characterized by complementmediated hemolytic anemia, thrombophilia and bone marrow failure. The clinical hallmark of PNH is evide... |
|
|
The role of complement inhibition in PNH. Hillmen P.
Hematology Am. Soc. Hematol. Educ. Program 2008(1) , 116-123, (2008)
|